LTUS-- FD shares is now 53.7M
Seems they could have EPS for 2010 of 0.40 or more.
From the Q1 10-Q:
First Quarter 2010 Highlights and Recent Developments:
-- Diluted EPS of $0.09, up 27% from first quarter 2009
-- Net revenues of $14.9 million, up 26% from first quarter 2009
-- Net income of $4.9 million, up 38% from first quarter 2009
-- Gross margin of 58%, as compared with 56% from first quarter of 2009
-- Net margin of 33%, as compared with 30% from first quarter of 2009
-- Reduced our current liability under the outstanding Series A Preferred Stock from $2,477,433 on March 31, 2010 to $621,333 May 13, 2010 due to the conversion of preferred shares to common stocks
-- Added five prescription drugs under the National Health Insurance Program to deliver through the wholesale channel nationwide, achieving the goal of increasing product for 2010
-- Continued Sarbanes-Oxley compliance project, to be fully and timely compliant in 2010
-- Commenced construction of the Beijing building complex which is scheduled for completion in 2010
-- Received SFDA's approval for R-Bambuterol(R) Hydrochloride Tablets to commence clinical trials as a Class 1 New Drug for special/fast track review
-- Approved extension of contract term from 10 years to 30 years between Lotus Pharmaceuticals, Inc.'s wholly-owned foreign enterprise and two operating entities in China
AI
